Heritage Bio Labs
Research Library
Explore 411 articles about peptides, research compounds and related topics, with links to the original studies.
Find articles
All articles
Showing 133–144 of 411 articles
- Interpret the evidence
How a cultured pituitary study separated receptor signals
GHRP-2 is a six-residue synthetic peptide also called pralmorelin. It activates the ghrelin receptor, also known as the growth hormone secretagogue receptor. How did researchers distinguish its signaling from that of the natural pituitary stimulus growth hormone–releasing hormone (GHRH)?
GHRP-22 sources (1998, 2025)
- Interpret the evidence
What the 2026 COURAGE-2 stroke trial found about a specific combination
Growth hormone–releasing peptide 6, or GHRP-6, is a synthetic six-residue peptide that activates the ghrelin receptor and can stimulate growth hormone release. In 2026, a clinical trial reported whether a combination containing GHRP-6 improved disability after acute ischemic stroke.
GHRP-62 sources (2021, 2026)
- Check methods and identity
What a rat stroke experiment measured in tissue near the injury
GHRP-6 is a six-residue synthetic growth hormone secretagogue and ghrelin-receptor agonist. A 2026 animal study examined the proteins that changed after GHRP-6 and epidermal growth factor (EGF) were given together in a stroke model.
GHRP-63 sources (2021, 2026)
- Understand the science
How a 2026 experiment studied cardiac remodeling after a blocked artery
GHRP-6, short for growth hormone–releasing peptide 6, is a six-residue peptide that activates the ghrelin receptor. In March 2026 researchers reported what happened when they studied GHRP-6 after a coronary artery was permanently blocked in rats.
GHRP-62 sources (2021, 2026)
- Understand the science
How a six-residue peptide can fit the ghrelin receptor
GHRP-6 is a synthetic six-residue growth hormone–releasing peptide that activates the ghrelin receptor. How can it activate the same receptor as ghrelin, a longer natural hormone with a different chemical structure?
GHRP-61 source (2021)
- Explore study findings
Why preventing a raised scar differs from reversing one
GHRP-6 is a synthetic six-residue peptide that activates the ghrelin receptor and promotes growth hormone release in experimental settings. An animal study asked whether exposure to GHRP-6 changed the development of a raised scar or the appearance of an already mature scar.
GHRP-62 sources (2018, 2021)
- Explore study findings
Why a human blood study reported two half-lives
GHRP-6 is a six-residue synthetic growth hormone–releasing peptide. In a small human study, researchers asked which mathematical model best described the decline of GHRP-6 itself in blood. No recent primary human study directly repeating this time-course experiment was identified.
GHRP-61 source (2012)
- Check methods and identity
Why the GLOW Name Does Not Identify a Single Peptide
GLOW is a catalog name for a blend, rather than the name of one defined peptide. The formulation discussed here refers to three named components: GHK-Cu, BPC-157 and material labeled TB-500.
GLOW Blend3 sources (2026)
- Interpret the evidence
What an Achilles Tendon Study Can Tell Us About Two GLOW Components
GLOW is a blend label that can include BPC-157, a material called TB-500 and GHK-Cu. A 2026 study addresses the first two names in a rat model, which makes it useful for understanding the component evidence. The experiment did not test the three-component GLOW mixture.
GLOW Blend2 sources (2026)
- Explore study findings
Why Copper’s Chemical Form Matters When Reading GLOW Research
Peptides are short chains made by linking amino acids through peptide bonds. A chain can sometimes bind a metal ion. That is the case for GHK-Cu, the copper complex of a three-amino-acid peptide and one ingredient named in descriptions of GLOW.
GLOW Blend1 source (2026)
- Explore study findings
What a Copper Peptide Hydrogel Study Adds to the GLOW Discussion
GLOW is a label for a mixture of research materials that can include GHK-Cu, a peptide bound to copper. A 2026 paper used GHK-Cu in an engineered hydrogel for an infected diabetic wound model.
GLOW Blend1 source (2026)
- Understand the science
How to Read a Claim That GLOW Ingredients Work Better Together
GLOW is a label sometimes used for material containing GHK-Cu, BPC-157 and TB-500. A claim that the ingredients work better together requires a comparison of the actual blend with the relevant components. Separate papers about different tissues and endpoints do not make that comparison.
GLOW Blend2 sources (2026)
Browse by product
- A4 Amyloid Beta6 articles
- ACE-0316 articles
- ACE-0836 articles
- Adipotide6 articles
- AICAR6 articles
- AOD-96046 articles
- ARA-2906 articles
- BPC-1576 articles
- BPC-157 / TB-5006 articles
- Cagrilintide7 articles
- CJC-1295 (No DAC) / GHRP-26 articles
- CJC-1295 (No DAC) / GHRP-66 articles
- CJC-1295 (No DAC) / Ipamorelin6 articles
- CJC-1295 No DAC6 articles
- CJC-1295 With DAC6 articles
- DSIP6 articles
- Epitalon6 articles
- Follistatin 3156 articles
- Follistatin 3446 articles
- Fragment 176-1916 articles
- GHK-Cu6 articles
- GHRP-26 articles
- GHRP-66 articles
- GLOW 2 Blend6 articles
- GLOW Blend6 articles
- GLP-1 SEMA6 articles
- GLP-2 TIRZ6 articles
- Glutathione6 articles
- HCG6 articles
- Hexarelin6 articles
- Human Relaxin-26 articles
- IGF-1 DES 1,36 articles
- IGF-1 Human6 articles
- IGF-2 LR36 articles
- IGF-DES 1,36 articles
- IGF-LR36 articles
- Ipamorelin6 articles
- Kisspeptin-106 articles
- KLOW Blend6 articles
- KPV6 articles
- Lipopeptide6 articles
- Liraglutide6 articles
- Melanotan II5 articles
- MGF6 articles
- MOTS-C6 articles
- MSC Exosomes6 articles
- Myostatin6 articles
- Myostatin HMP (GDF8)6 articles
- Oxytocin7 articles
- PEG-MGF6 articles
- Pinealon6 articles
- PT-1416 articles
- RETA / IGF-1 LR36 articles
- RETA GLP-36 articles
- Selank6 articles
- SEMA / IGF-1 LR36 articles
- Semax6 articles
- Sermorelin6 articles
- SLU-PP-3326 articles
- SNAP-86 articles
- Survodutide7 articles
- TB-5006 articles
- Tesamorelin6 articles
- Thymosin Alpha-16 articles
- TIRZ / IGF-1 LR36 articles
- TIRZ GLP-26 articles
- Trevogrumab6 articles
- Triptorelin GnRH6 articles
